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  39 
Abstract	  40 
A major outbreak of whooping cough, or pertussis, occurred in 2012 in the U.K, with 41 
nearly 10 000 laboratory-confirmed cases and 14 infant deaths attributed to pertussis. 42 
A worldwide resurgence of pertussis has been linked to switch to the use of acellular 43 
pertussis vaccines and the evolution of B. pertussis away from vaccine-mediated 44 
immunity. We have conducted genomic analyses of multiple strains from the UK 45 
outbreak. We show that the UK outbreak was polyclonal in nature, caused by multiple 46 
distinct but closely related strains. Importantly, we demonstrate that acellular vaccine 47 
antigen encoding genes are evolving at higher rates than other surface protein 48 
encoding genes. This was true even prior to the introduction of pertussis vaccines, but 49 
has become more pronounced since the introduction of the current acellular vaccines. 50 
The fast evolution of vaccine antigen genes has serious consequences for the ability of 51 
current vaccines to continue to control pertussis.	  52 
 53 
Keywords: Pertussis, genomics, evolution, vaccine 54 
 55 
Introduction	  56 
Whooping cough, or pertussis, is caused primarily by the bacterium Bordetella 57 
pertussis. In England and Wales a total of 9,711 laboratory-confirmed cases were 58 
recorded in 2012, leading to fourteen deaths in infants under 3 months of age. This 59 
was much greater than the previous recent	   ‘peak’	  year in 2008, in which 902 cases 60 
were reported despite levels of vaccine coverage and diagnostic methods not changing 61 
during this period [1, 2]. Similar outbreaks have been reported across the globe [3], 62 
contributing to the consensus that pertussis is a resurgent disease that might be no 63 
longer effectively controlled by current vaccination programmes.	  64 
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 65 
Resurgence has been linked to increased surveillance, better diagnostic techniques, 66 
incomplete vaccination of populations but primarily to switching from the use of 67 
whole cell (WCV) to acellular (ACV) pertussis vaccines that contain between 1 and 5 68 
purified B. pertussis protein antigens: pertussis toxin (Ptx), filamentous 69 
haemagglutinin (FHA), pertactin (Prn) and fimbrial types 2 and 3 (Fim2/Fim3). In the 70 
UK, a five antigen ACV has been used. ACV induced immunity appears shorter lived 71 
than that induced by WCVs, possibly resulting in an expanded pool of carriers, 72 
particularly adolescents, and decreased herd immunity	   [4,	   5]. In addition, studies 73 
using an infant baboon model revealed that while ACVs protect the individual from 74 
disease symptoms, they are less able to prevent colonisation of, and transmission 75 
from, the vaccinee compared to WCVs.  Increased transmission of B. pertussis in 76 
populations using ACVs compared to those using WCVs is proposed to contribute to 77 
resurgence	  [6]. Finally, it has been proposed that vaccine escape mutants are arising, 78 
as ACV-induced immunity is focused on just a few antigens, and changes in these 79 
antigens might result in strains that are less well recognised by this immunity [7].	  80 
 81 
The frequency of different alleles of vaccine antigen genes among strains has changed 82 
over time [8-11]. The most common allelic profile among currently circulating strains 83 
(ptxA1-ptxP3, prn2, fim3-2, fim2-1) is different to that of strains used for vaccine 84 
manufacture [12,	  13] and isolates that do not express Prn are increasingly common 85 [14-­‐16]. PtxP refers to alleles of the ptx promoter. PtxP3 is now dominant worldwide 86 [17] and some studies suggest that ptxP3 strains may have increased virulence 87 
compared to ptxP1 strains [18]. 88 
 89 
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The study of genetic changes in B. pertussis over time was hindered by the high levels 90 
of homogeneity among B. pertussis and the lack of fine-resolution tools. Thus 91 
recently the genome sequences of a large panel of B. pertussis strains collected from 92 
around the world and across many decades were generated and analysed [19].	  This 93 
provided detailed information about the population structure and evolution of B. 94 
pertussis revealing significant genetic changes among strains over the last 50 years. A 95 
lack of geographical clustering of strains suggested rapid strain flow between 96 
countries. However, this panel of strains did not contain isolates collected more 97 
recently than 2008, except for 3 isolates from the Netherlands collected in 2009 and 98 
2010, and did not intensively sample a specific outbreak meaning that the genetic 99 
make-up of such events is largely unknown. Here we analyse a large panel of UK 100 
strains with a focus on strains from the recent UK outbreak with the aims of 101 
understanding the clonal structure of the outbreak and determining if there is evidence 102 
for vaccine-mediated immunity driving the evolution of these strains.	  103 
 104 
Methods	  105 
Accession Numbers	  106 
Genome sequence data has been deposited in the European Nucleotide Archive 107 
(ENA) (http://www.ebi.ac.uk/ena/), Supplementary Table 1.	  108 
 109 
B. pertussis Strains	  110 
100 B. pertusiss isolates were obtained from the National Reference Laboratory, 111 
Respiratory and Vaccine Preventable Bacteria Reference Unit at Public Health 112 
England (Supplementary Table 1). Five strains were collected between 1920-1956 113 
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(we define this as the ‘pre-vaccine’ era), six strains collected between 1957-2000 114 
(WCV era) and 89 strains were collected between 2000-2012 (ACV era). Serotyping 115 
was performed using sera specific for antigens 1, 2, and 3 (89/596, 89/598, and 116 
89/600, respectively; National Institute for Biological Standards and Controls, Potters 117 
Bar, United Kingdom) as previously described [12]. Tohama I (accession number 118 
BX470248), a strain isolated in Japan in 1954, is the most widely studied strain, 119 
provides the reference genome sequence of B. pertussis [20], and is one of the strains 120 
used to produce ACVs used in the UK.  B. pertussis isolates were grown on charcoal 121 
agar for 72 hours at 37°C.   	  122 
 123 
DNA Preparation	  124 
Genomic DNA extraction was performed using the Qiagen DNA prep kit according to 125 
the manufacturer’s instructions.	  126 
 127 
DNA Sequencing and Single Nucleotide Polymorphism (SNP) Identification	  128 
Twenty four isolates were sequenced previously [19]. For the remainder, multiplex 129 
libraries, with fragment sizes between 300 and 500bp, were prepared as previously 130 
described [21]	  with	  modifications [22]. Reads for each isolate were aligned to the 131 
Tohama I reference genome using SMALT version 0.7.4 132 
(http://www.sanger.ac.uk/resources/software/smalt/). Base calls were made as 133 
previously described [21], using a combination of samtools, mpileup and bcftools 134 [23], allowing SNPs, and small insertions and deletions relative to Tohama I to be 135 
identified. Five strains produced poor quality sequence and were excluded from the 136 
analysis, resulting in 95 strains being taken forward for analysis.	  137 
 138 
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Phylogenetic Analysis	  139 
Maximum likelihood phylogenetic analysis was carried out on variable sites from 140 
across the whole genomes using RAxML under a GTR evolutionary model and a 141 
gamma correction for among site rate heterogeneity [24]. 100 random bootstrap 142 
replicates were run to provide support for relationships identified in the tree.	  143 
 144 
Analysis of SNP Densities	  145 
SNPs were reconstructed on to the phylogenetic tree using parsimony. SNP densities 146 
(SNP/bp) within vaccine antigen genes (9 genes: fhaB, prn, fim2, fim3, ptxA-E) or 147 
‘cell surface’ functional category genes (591 genes, as categorised previously [20]) 148 
were calculated by counting the number of SNPs per bp of each gene. The difference 149 
between the mean per gene SNP densities of vaccine antigen genes and cell surface 150 
genes was calculated. The significance of this difference was calculated using a non-151 
parametric Monte Carlo simulation. In our randomizations of all the data, preserving 152 
relative sample sizes, it was observed how often a difference as large, or greater than 153 
the difference above, by repeated randomly resampling two samples of the same size 154 
as above. Under this protocol, if n is the number of observations that have greater than 155 
or equal to the observed difference in SNP density and m is the number of simulations 156 
(in this case, 10 000), then P= (n+1)/(m+1) is the unbiased estimator.	  157 
 158 
We performed a similar procedure to compare SNP densities in vaccine antigen genes 159 
between eras. To account for differences in SNP densities between strains from the 160 
different eras, the SNP densities of the vaccine antigen genes were normalised by the 161 
SNP densities of all the genes considered (vaccine antigen and surface protein 162 
encoding genes). A non-parametric Monte Carlo simulation compared the normalised 163 
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SNP densities in the ACV antigen genes in ACV-era strains with pre-ACV era strains, 164 
with P determined as above.	  165 
 166 
Allele Typing	  167 
The different alleles of prn, ptxA, ptxP, fim3 and fim2 genes have been previously 168 
described [11] and were used to identify allele types from DNA sequence.	  169 
 170 
Analysis of prn from UK50	  171 
The prn locus was amplified from UK50 by PCR using primers 5′-172 
CCGCTGATTCGCCACAAG-3′	   and 5′-GTGCGGTACTTGCCCTTG-3′. PCR 173 
products were cloned using the Gateway system (Invitrogen, Paisley, U.K.) and 174 
sequenced by Eurofins Genomics (Ebersberg, Germany) utilising standard M13 175 
forward and reverse primers and internal primers 5′-GCGCACGCCTGTCCAAAG-3′	  176 
and 5′-TAGCGAGCCAGCACGTAG-3′.	  177 
 178 
Analysis of Differences in DNA Content Among Strains	  179 
To detect gene loss from strains, compared to the DNA content of Tohama I, coverage 180 
plots generated using the paired end reads mapped to this reference genome were used 181 
to create a heat map. DNA sequence contigs that did not map to Tohama I were 182 
analysed using Blastn and Blastx (http://blast.ncbi.nlm.nih.gov/Blast.cgi).	  183 
 184 
Results	  185 
Phylogeny of UK Strains from 1920-2012	  186 
Phylogenetic analysis based on SNPs across the whole genome sequences was 187 
performed to understand the evolutionary relationships between the UK strains 188 
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analysed (Fig.1, Suppl. Table 1). Strains isolated during 1920-1982 form a cluster and 189 
are generally separated from strains from 2008-2012. The most distinct clustering 190 
separates strains carrying the ptxP1 allele from those carrying the ptxP3 allele, which, 191 
as found elsewhere, is the predominant ptxP type among recent strains. This 192 
phylogenetic analysis was extended to place the UK strains in the global phylogenetic 193 
tree described elsewhere [19] (Fig. 2). This reveals that the UK ptxP3 strains separate 194 
into two clusters, distinguished by the presence of the fim3-2 allele. The UK outbreak 195 
strains largely cluster with strains isolated mainly during the early 2000s from a 196 
variety of geographical areas including North America, Europe and Australia. 	  197 
 198 
Vaccine antigen allele profiles	  199 
Previously, ptxP3-ptxA1-prn2-fim3-2 was defined as the dominant allele type 200 
circulating in the UK and other countries [17]. Typing of alleles among the outbreak 201 
strains reveal no recent change in this profile (Table 1). Numerous isolates deficient 202 
for the production of Prn have been reported in other countries, and a number of 203 
different mutations in prn responsible for this phenotype identified [14-­‐16]. It has 204 
been suggested that loss of Prn expression has been selected by vaccine-mediated 205 
immunity pressure. Interestingly, just a single UK strain, UK50, was mutated for prn. 206 
This was identified by a lack of sequence reads mapping to a region of prn. The prn 207 
locus was amplified by PCR from this strain and the resulting product sequenced 208 
using Sanger sequencing. This identified that a recombination event between two 209 
copies of IS1663 has resulted in a deletion/insertion mutation in which the 5′	  1326 bp 210 
of the prn coding sequence has been deleted. Aberrant mapping was not observed for 211 
any other UK strain. In other countries, a common prn mutation arose from insertion 212 
of IS481 into prn. We identified paired-end reads in which one read mapped within 213 
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IS481 but the other did not and thus derives from the region flanking IS481. Mapping 214 
these reads to the reference genome identified the position of the copies of IS481 215 
within each query strain. No IS481 insertions into prn were identified among UK 216 
strains. It is not clear why so few Prn-deficient strains, compared to other countries 217 
experiencing pertussis outbreaks, have been identified in the UK.	  218 
 219 
SNPs Specific to ptxP3 Strains	  220 
PtxP3 strains are the predominate type in current circulation and appear to have 221 
different infection biologies compared to ptxP1 strains. The ptxP3 SNP itself appears 222 
to be both a direct cause and a marker for other genetic variations that contribute to 223 
this difference [18]. To investigate the genetic traits of UK ptxP3 strains, SNPs 224 
specific to this lineage were identified. In total, 22 such SNPs were identified (Table 225 
2). Ten were intergenic, seven of which were in the direct repeat region of IS 226 
elements which are present in multiple copies in the B. pertussis genome. It is not 227 
clear if these particular IS elements are functional. Twelve SNPs were in coding 228 
regions.  Of those, seven were non-synonomous mutations (NSM) and 5 were 229 
synonymous (SM). The 7 NSM were in genes within the “transport and binding 230 
proteins”, “pseudogene”, “conserved hypothetical”, “virulence-associated”, 231 
“unknown”	  and “regulation”	  functional categories as defined previously [20].   All of 232 
these SNPs were also identified among the global panel of B. pertussis strains [19]. 233 
However, of the 22 SNPs identified here as being ptxP3-specific, only 10 were 234 
identified as being ptxP3-type-specific in the previous study (Table 2), the other 12 235 
SNPs were also identified among non-ptxP3 strains globally. 236 
 237 
SNP Rates are high in Vaccine Antigen Encoding Genes	  238 
 11	  
Previously, it was identified that genes in the ‘cell surface’	   functional category had 239 
higher SNP densities than the B. pertussis chromosomal average [19]. However, 240 
ACV vaccine-mediated immunity is exerting selective pressure primarily on the 241 
proteins used in these vaccines and might be driving their evolution. To explore this, 242 
the SNP density (SNPs per bp) for the 9 ACV antigen genes (Ptx comprises five 243 
different proteins) and for the other 591 genes comprising the ‘cell surface’ category 244 
was calculated for all strains within each vaccine era and compared. Secondly, it was 245 
investigated if the SNP rate in ACV genes had increased since the introduction of 246 
ACVs.	  247 
 248 
The difference in mean SNP density across genes within the two samples (mean SNP 249 
density in vaccine antigen genes minus mean SNP density in cell surface genes) was 250 
calculated. A non-parametric Monte Carlo simulation was used to assess the 251 
significance of this difference by determining how often a difference as large or larger 252 
than this was derived by randomly resampling two samples the same size as above, 253 
from the pool of vaccine antigen and cell surface genes. This revealed that in each era, 254 
vaccine antigen encoding genes had significantly higher SNP densities than other cell 255 
surface genes (P<0.05, Table 3), with the difference being greatest among ACV-era 256 
strains. This suggests that the vaccine antigen genes are faster evolving than other 257 
surface protein encoding genes, and that they were also faster evolving even prior to 258 
the introduction of widespread vaccination. 	  259 
 260 
To compare SNP densities in vaccine antigen genes between eras, SNP densities 261 
within each era were normalised by dividing by the mean SNP rate across all of the 262 
genes concerned (ACV antigens and cell surface). In comparison to the prior analysis 263 
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this has less power owing to the much smaller sample of ACV genes compared with 264 
total cell surface genes. Although the normalised SNP density in ACV-era strains was 265 
greater than in pre-ACV era strains, the difference was not statistically significant, 266 
P=0.160. However, the number of pre-ACV strains in this analysis was small. Thus, 267 
the same analyses were repeated using SNP data from the global collection of strains, 268 
for which the year of isolation was known [19], and incorporating the UK strains 269 
sequenced here, Table 3. Again, a significantly greater SNP frequency was found in 270 
ACV antigen genes than other cell surface genes, in all of the three eras. This time, 271 
there was also a significantly higher SNP frequency in ACV genes among ACV era 272 
strains compared to pre-ACV era strains (P=0.0177) suggesting that the relative SNP 273 
density in ACV antigen genes has increased since the introduction of ACVs. These 274 
results suggest that ACV genes are intrinsically fast evolving and provide some 275 
support for the hypothesis that they are even faster evolving since the introduction of 276 
ACVs.	  277 
 278 
The more rapid evolution in the ACV antigen genes could be due to either a higher 279 
underlying mutation rate or different selection at the protein level.  The different 280 
selection could be positive selection or weaker purifying selection. To distinguish 281 
between these two possibilities, SNPs were split into SM and NSM. High NSM but 282 
not SM rates would suggest altered protein-level selection.  A higher rate of 283 
synonymous evolution (with possibly a weak non-synonymous effect) would suggest 284 
higher mutation rates.  Interpretation here is difficult owing to well-described but 285 
incompletely understood correlation between synonymous and non-synonymous rates.	  286 
 287 
 13	  
Among WCV- and ACV-era global strains, but not pre-vaccine era strains, the SM 288 
frequency was significantly higher in ACV antigen genes compared to other cell 289 
surface genes, Table 4. When comparing ACV-era to pre-ACV era strains, the SM 290 
frequency in ACV antigen genes was significantly higher (P=0.004). NSMs also 291 
occurred at significantly greater frequency in ACV antigen genes compared to other 292 
cell surface genes (Table 4).  The magnitude of this effect is greater than that seen for 293 
SMs suggesting the higher evolutionary rate of ACV antigen genes compared to cell 294 
surface proteins is largely owing to protein-level selection on the antigens.  Evidence 295 
for a strong recent increase is less clear-cut. When comparing strains from the ACV-296 
era to pre-ACV era strains, the NSM frequency in ACV antigen genes was on the 297 
edge of significance (P=0.051). Overall, our results provide support for the hypothesis 298 
that the genes encoding antigens chosen for ACVs are intrinsically fast evolving, in 299 
part owing to selection on their antigenic products. We cannot discount the possibility 300 
that in the ACV-era there has been an increase in the mutation rate (but see also 301 
below).	  302 
 303 
Regions of Difference	  304 
Deletions have been a major feature of B. pertussis evolution and appear to be on-305 
going [20,	   25]. Compared to the Tohama I reference genome, most of the major 306 
deletions observed among the strains analysed here had been identified previously 307 [25]. Numerous small deletions were found in only a few, or just one isolate, 308 
suggesting that deletion of DNA is common among B. pertussis strains. Interestingly, 309 
some deletions appeared specific to the UK ptxP3 strains but no deletions specific to 310 
outbreak isolates were detected (Suppl. Fig 1).	  311 
 312 
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Regions from individual strains that were not present in the Tohama I reference 313 
genome were investigated by BLAST analyses. These regions were also found within 314 
other B. pertussis genomes (BP18323 and CS), or in B. bronchiseptica RB50, similar 315 
to that reported in other studies [26].  Thus there were no novel insertions or gene 316 
acquisition among outbreak isolates.	  317 
 318 
Discussion	  319 
The resurgence of pertussis in countries with high levels of vaccination has caused 320 
widespread concern. Among other factors, B. pertussis evolution away from efficient 321 
control by vaccine-induced immunity has been proposed as a contributor to this. 322 
Recently, whole genome sequencing was used to define global genetic variability 323 
among B. pertussis isolates and this identified genetic changes in the B. pertussis 324 
population over time [19]. 	  325 
 326 
Here we have analysed in detail the genomes of UK B. pertussis isolates with 327 
emphasis on strains from the 2012 outbreak. For the first time we show that many 328 
genetically distinct B. pertussis strains contributed to this outbreak and importantly, 329 
that it was not due to the emergence of a novel, hypervirulent clone or expansion of 330 
an individual lineage. Furthermore, outbreak strains were genetically very similar to 331 
those circulating during periods when the incidence of pertussis was low.	  332 
 333 
The ptxP3 type is the dominant clone world-wide and UK outbreak strains are also 334 
predominantly of this type. Analysis of global isolates identified just 19 SNPs as 335 
being ptxP3–specific [19]. Here, 22 SNPs distinguished ptxP3 from ptxP1 strains. 336 
However, just 10 of these were common to both sets of ptxP3-specific SNPs. If ptxP3 337 
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strains have increased fitness or virulence compared to older isolates, our analysis 338 
suggests that very few SNPs are responsible for this, or that particular combinations 339 
of SNPs are important, only some of which are ptxP3-specific. Overall, these data 340 
argue against large-scale genetic changes being behind the recent resurgence in 341 
pertussis.	  342 
 343 
Changes in alleles of the genes encoding vaccine antigens have been well documented 344 
(for example, [27]) and supports the hypothesis that selection pressure from ACV 345 
induced immunity is a driver of B. pertussis evolution. However, definitive studies to 346 
demonstrate that allelic variation enhances evasion of vaccine-mediated immunity are 347 
lacking and particularly difficult to perform given the inability to conduct studies with 348 
human hosts and that studies using animal models struggle to detect subtle changes 349 
and will not include population level effects that are certainly important for selection 350 
of variants among B. pertussis worldwide. Here we provide compelling evidence that 351 
genes encoding ACV antigens are evolving more rapidly than other cell surface genes 352 
(which we consider the most suitable comparator group), containing a significantly 353 
higher frequency of SNPs in each of the vaccine eras. Interestingly, this was true even 354 
in the pre-vaccine era. It is likely that even in the absence of vaccination, the natural 355 
immune response to these antigens creates selective pressure, particularly for a 356 
pathogen that is restricted to the human respiratory tract. Of particular importance is 357 
that we calculated that ACV antigen gene evolution rates have increased significantly 358 
since the introduction of ACVs, the first demonstration of this effect. This might 359 
suggest that the use of ACVs has increased selection pressure on ACV antigens, 360 
selecting for ACV antigen gene variants. However, we also calculated that while the 361 
frequency of SM in ACV antigen genes was significantly higher in ACV era strains 362 
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compared to older strains, the frequency of NSM was on the edge of significance 363 
(P=0.051). In turn this suggests that selection pressure from vaccine-mediated 364 
immunity is not the sole driving force for ACV antigen gene variation. A different 365 
interpretation is that the mutation rate of ACV antigen genes has increased since the 366 
introduction of ACVs. If synonymous sites are under weak purifying selection (i.e. 367 
not perfectly neutral), then there is a lag between a SNP arising and its elimination by 368 
this selection, resulting in an excess of SNPs in the modern era. However, normalising 369 
ACV gene SNP rates by the SNP rates for all genes within the era largely eliminates 370 
this effect (i.e. SMs in cell surface genes should be equally over-represented in the 371 
modern era). However, if SMs in ACV genes and cell surface genes are under 372 
different intensities of purifying selection, then our result could be found.	  373 
 374 
Either way, the more rapid evolution at the protein level (as determined by NSM) of 375 
ACV proteins compared to other cell surface proteins, across all eras suggests that 376 
strains will become increasingly mismatched to those used for vaccine production and 377 
this could lead to decreased vaccine efficacy over time. The ACV antigens were 378 
chosen on the basis of their immunogenicity but it could be that this property has 379 
driven the relatively high evolution rates of the genes encoding these antigens. Our 380 
results raise fresh concerns over the ability of current acellular pertussis vaccines to 381 
continue to control disease.	  382 
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 467 
Figure Legends.	  468 
Figure 1. Phylogenetic tree depicting the evolutionary relationships among the UK B. 469 
pertussis isolates studied here. Maximum likelihood (ML) phylogenetic analysis was 470 
carried out on variable sites from across the whole genomes using RAxML. Strains 471 
are shaded according to their year of isolation and ptxP type.	  472 
 473 
Figure 2. Phylogenetic relationships of UK strains within a global context. The UK 474 
isolates analysed here are indicated.	  475 
 476 
Supplemental Table 1.	  477 
Details of strains analysed in this study.	  478 
 479 
Supplemental Figure 1.	  480 
A heat map of coverage plots of the sequence reads of each UK strain mapped to the 481 
Tohama I reference genome. Black regions indicate sequence common to both query 482 
and reference genomes, white regions indicate regions of the reference genome that 483 
are absent from the query strain genomes. 484 
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Table 1. Frequency (% of strains tested) of vaccine antigen encoding gene alleles 485 
among UK strains. 486 
 
 
           Period  
 Prevaccine 
1920-1956 
WCV 
1957-2000 
ACV 
2001-2012 
No. of strains 
5 6 84 
ptxP   1 
           3 
100 
0 
100 
0 
6 
94 
ptxA    1 
            2 
20 
80 
100 
0 
100 
0 
*Prn    1 
            2 
            3 
            4 
100 
0 
0 
0 
84 
0 
16 
0 
5 
91 
3 
1 
Fim2-  1 100 100 100 
Fim3-  1 
            2 
            3 
100 
0 
0 
100 
0 
0 
70 
29 
1 
**Serotype 1 
                 1,2 
                 1,3 
              1,2,3 
20 
40 
20 
20 
0 
50 
17 
33 
0 
37 
63 
0 
 487 
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*Prn allele type was determined for just 76 ACV era strains due to poor mapping of 488 
reads in this region in 8 strains. 489 
** Serotype was not determined for one ACV era strain, thus frequencies are based on 490 
83, not 84, strains in this era. 491 
  492 
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Table 2. SNPs specific to UK ptxP3 strains. 493 
Locationa 
Typeb Mutationc Global 
ptxP3d 
Details 
36857 INT A:G Yes 93 bp upstream of BP0032 (encoding a 
putative transport protein), 156bp upstream of 
BP0033 (encoding GlyQ-glycyl-tRNA 
synthetase alpha chain) 
617083 
INT T:G No within the 5' repeat region of IS481 (BP0611). 
31bp upstream of transposase start codon. 
617084 INT C:T No within the 5' repeat region of IS481 (BP0611). 
32bp upstream of transposase start codon. 
1077844 
INT C:T No within the 5' repeat region of IS1663 
(BP1035). 139bp upstream of transposase 
start codon. 
1170424 INT A:G No within the 5' repeat region of IS481 (BP1114). 
31bp upstream of transposase start codon. 
1222400 INT A:C No within the 5' repeat region of IS481 (BP1157).  
31 bp upstream of transposase start codon. 
1635654 INT T:G No within the 5' repeat region of IS481 (BP1557). 
31 bp upstream of transposase start codon. 
2259917 INT G:C No within the 5' repeat region of IS481 (BP2135). 
98 bp upstream of transposase start codon. 
3263622 INT A:C Yes 193 bp away from BP3062. Putative integral 
membrane transport protein. 
3988168 INT G:A Yes 89 nucleotides away from the start codon of 
 24	  
ptxA.  ptxP3allele. 
196307 
NSM T:C  Yes BP0194. Putative transport protein. 
299559 
NSM  C:T Yes BP0292. Pseudogene. Conserved hypothetical 
protein. 
1331840 
NSM G:A Yes Pseudogene. BP1261. Hypothetical protein. 
1547488 
NSM A:G No BP1471. Conserved hypothetical protein. 
2374322 
NSM T:C Yes BP2249. BscI. Type III secretion apparatus 
protein. 
2651008 
NSM G:A Yes BP2502. Hypothetical protein. 
3134458 
NSM G:C No BP2946. Probable transcriptional regulator. 
185405 
SM  G:A  No BP0184. Putative periplasmic protein. 
518837 
SM  T:C No BP0507. Putative membrane protein.  
694521 
SM  A:G Yes BP0678. Putative peptide chain release factor.  
3840411 
SM  G:A Yes BP3630. RpsH. 30S ribosomal protein. 
3991376 
SM  C:T No BP3787. PtxC. Pertussis toxin subunit 
protein. 
a Tohama I reference genome coordinates (accession no. BX470248) . 494 
b Int: SNP is in an intergenic region. NSM: non-synonymous mutation, SM:  495 
synonymous mutation. 496 
c e.g. C:T – C to T mutation. 497 
d SNP is also defined as ptxP3-specific in study of global B. pertussis population (1). 498 
  499 
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Table 3. 500 
SNP rates in vaccine antigen encoding genes compared to other cell surface genes for 501 
the different vaccine eras among UK strains and globally. 502 
 503 
  504 
Vaccine era. 
(No. of strains) 
 
mean SNP/bp 
vaccine 
antigen 
genes 
mean 
SNP/bp cell 
surface 
genes 
Diffference 
(vaccine 
antigens - cell 
surface) 
Difference 
normalized 
(Difference/mean 
SNP density) 
P (SNP rate 
vaccine antigens 
> SNP rate cell 
surface) 
UK Pre- 
1920-1956 
(5) 
3 x10-4 7.8 x10-5 2.22 x10-4 2.72 0.045 
UK WCV 
1957-2000 
(6) 
4.75 x10-4 5.9 x10-5 4.17 x10-4 6.40 0.016 
UK ACV 
2001-2012 
(84) 
1.73 x10-3 1.55 x10-4 1.57 x10-3 8.82 0.0004 
Global Pre- 
1920-1956 
(19) 
1.45 x10-3 5.85 x10-4 8.62 x10-4 1.44 0.012 
Global WCV 
1957-2000 
(204) 
2.62 x10-3 1.01 x10-3 1.61 x10-3 1.56 0.002 
Global ACV 
2001-2012 
(188) 
2.91 x10-3 4.23 x10-4 2.49 x10-3 5.41 0.0001 
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Table 4. Synonomous (SM) and non-synonomous (NSM) mutation rates in vaccine 505 
antigen genes compared to other cell surface genes among strains isolated during the 506 
different vaccine eras.  507 
 508 
Vaccine era. 
(No. of strains) 
 
mean SNP/bp 
vaccine 
antigen genes 
mean 
SNP/bp cell 
surface 
genes 
Diffference 
(vaccine 
antigens - cell 
surface) 
Difference 
normalized 
(Difference/mean 
SNP density) 
P (SNP rate 
vaccine antigens 
> SNP rate cell 
surface) 
SM 
Global Pre- 
1920-1956 (19) 
1.32 x10-4 2.4 x10-4 -1.07 x10-4 -0.45 0.627 
SM 
Global WCV 
1957-2000 (204) 
9.66 x10-4 4.23 x10-4 5.43 x10-4 1.26 0.045 
SM 
Global ACV 
2001-2012 (188) 
9.68 x10-4 1.76 x10-4 7.92 x10-4 4.20 0.011 
NSM 
Global Pre- 
1920-1956 (19) 
1.18 x10-3 3.40 x10-4 8.38 x10-4 2.38 0.006 
NSM 
Global WCV 
1957-2000 (204) 
1.96 x10-3 5.83 x10-4 1.37 x10-3 2.28 0.002 
NSM 
Global ACV 
2001-2012 (188) 
1.95 x10-3 2.38 x10-4 1.71 x10-3 6.48 0.0002 
 509 
  510 
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 511 
 512 
  513 
0.019
Ye
ar
ptx
P
Year
1920
1942
1946
1947
1949
1964
1967
1979
1982
1983
1998
2002
2006
2008
2009
2010
2011
2012
ptxP
ptxP1
ptxP3
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 514 
UK 2012
UK prior to 2012
Non-UK
Key
0.0049
